#### 507188302 03/21/2022

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7235149

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
ERIN ADAMS	03/15/2018

# **RECEIVING PARTY DATA**

Name:	THE UNIVERSITY OF CHICAGO
Street Address:	5801 S ELLIS AVENUE
City:	CHICAGO
State/Country:	ILLINOIS
Postal Code:	60637

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Patent Number:	10457682

## **CORRESPONDENCE DATA**

Fax Number: (503)494-4729

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

5034948200 Phone: Email: ipmgmt@ohsu.edu

Correspondent Name: **OREGON HEALTH & SCIENCE UNIVERSITY** 

Address Line 1: 3181 SW SAM JACKSON PARK RD

Address Line 2: MAIL CODE L106TT

Address Line 4: PORTLAND, OREGON 97239

ATTORNEY DOCKET NUMBER:	2317
NAME OF SUBMITTER:	BRANDY BURTIS
SIGNATURE:	/Brandy Burtis/
DATE SIGNED:	03/21/2022

## **Total Attachments: 3**

source=2317\_Executed Assignments\_UofC#page1.tif source=2317\_Executed Assignments\_UofC#page2.tif source=2317 Executed Assignments UofC#page3.tif

PATENT **REEL: 059326 FRAME: 0856** 507188302

ASSIGNMENT

Pursuant to our obligation to THE UNIVERSITY OF CHICAGO ("ASSIGNEE"), an Illinois not

for profit corporation having its principal place of business at 5801 S. Ellis Avenue, Chicago, Illinois

60637, and for other valuable and sufficient consideration, receipt whereof is hereby

acknowledged, we:

**ERIN ADAMS** 

CARA FROYD

confirm that we have sold, assigned, and conveyed unto ASSIGNEE, its successors and assigns, or

to the extent we have not yet sold, assigned or conveyed, do hereby sell, assign and convey unto

ASSIGNEE, its successors and assigns, our entire right, title, and interest -

(1) in and to an invention entitled "Novel mycobacterial small molecules that bind

MR1 and are activating or antagonistic for MR1-restricted T cells (UCHI 2634)"

("INVENTION") for which we have filed United States Utility Application 15/667,893 entitled

"SMALL MOLECULES THAT BIND MR1" on October 20, 2017; which claims priority to US

Provisional Application 62/411,208 filed October 21, 2016; and

(2) In and to said United States patent applications, in and to all other patent applications

(including provisional, US Utility, PCT, divisional, continuation, continuation-in-part, §111(b)

provisional, §111(a), and reissue applications) based upon said invention, including the right to

claim priority to said Provisional patent application and to all other applications based upon said

invention, and in and to the patent or patents to be granted thereon, including reissues thereof,

if any, to the full end of the term or terms for which said patent or patents may be granted. The

effective date of this Assignment is October 21, 2016;

PCHICAGO

(3) in and to all patent applications based on INVENTION now or hereafter filed in

countries foreign to the United States of America, and in and to any and all patents granted on

said foreign applications to the full end of the term or terms for which said foreign patents may

be granted; AND

(4) in and to the right the claim the full benefits and priority rights under the International

Convention (and any other international agreement to which the United States adheres) in and

to any and all patent applications - both United States and foreign patent applications - based

on INVENTION now or hereafter filed.

And we hereby agree that, under the International Convention, any United States patent

application(s) and any foreign application(s) which may be filed shall be filed in the name of

ASSIGNEE with a claim to priority based on said United States Application.

And we hereby agree that we will, upon request of ASSIGNEE, its successors or assigns,

and without further consideration to us, execute any and all papers that may be necessary - or

deemed by ASSIGNEE, its successors or assigns, to be necessary – to a complete fulfillment of the

intents and purposes of this Assignment, it being understood that any expense incident to the

execution of such papers shall be paid by ASSIGNEE, its successors or assigns, and not by us.

UChicagoTech Assignment

Page 2 of 3

And the Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said United States patent or patents to ASSIGNEE.

3/15/18	A. Der
Date	ERIN ADAMS
3/15/19	Z.A.I
Date	Witness Signature
	John Leand
	Witness Printed Name
3/15/18	Caus Diesel
Date	CARA FROYD
3/15/18	
Date	Witness Signature
	Kristof Nolon
	Witness Printed Name
ACCEPTED:	
3/22/18	tatas 4
Date	CRISTIANNE FRAZIER Assistant Director, Technology Commercialization
	Polsky Center for Entrepreneurship and Innovation,

The University of Chicago

UChicagoTech\_Assignment

**RECORDED: 03/21/2022** 

Page 3 of 3